MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-18-0060879
Silaris Ingredients LLP
Silaris Ingredients LLP - pharma in Mumbai, Maharashtra, India. Directors, charges & compliance details.
Contribution obligation
₹20 Lakh
As per LLP agreement
LLP age
10 yrs
Est. 2016
Designated partners
4
As per MCA filings
Active GSTINs
1
GST registered
Last financials
Mar 2025
Balance sheet date
LLP status
Active
MCA master data
Registrar
Mumbai
ROC office
Incorporated
06 Jul 2016
Date of incorporation
About Silaris Ingredients LLP
Data last updated:
Silaris Ingredients LLP is a limited liability partnership (LLP) based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 July 2016 and has been in existence for over 10 years.
The LLP is registered with the Registrar of Companies (ROC), Mumbai, under LLPIN AAG-8584. Its GSTIN is 27ADCFS4924L1ZQ (Maharashtra).
The LLP has a total obligation of contribution of ₹20 Lakh. It is led by designated partners including Alpesh Sangani Ratilal and Bhavin Ratilal Sangani.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Office No.1002 Shree Radhey Empire Chandavarkar Road Borivali (W), Mumbai, Maharashtra, India – 400092.
Silaris Ingredients LLP is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0060879).
Company details
LLPIN AAG-8584
Incorporation Date 06 July 2016
Total Obligation of Contribution ₹20 Lakh
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 31 March 2025
Date of Balance Sheet 31 March 2025
MSME Classification Small
Udyam Registration UDYAM-MH-18-0060879
Key People
Alpesh Sangani Ratilal Designated Partner Bhavin Ratilal Sangani Designated Partner Durgesh Nath Tiwari Designated Partner Recognitions & Rankings of Silaris Ingredients
Contact details
Silaris Ingredients LLP's registered office is in Mumbai, Maharashtra.
- Registered AddressOffice No.1002 Shree Radhey Empire Chandavarkar Road Borivali (W), Mumbai, Maharashtra, India – 400092
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Silaris Ingredients LLP - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Financials of Silaris Ingredients LLP
FY 2025 filings availableFinancial Statement Summary
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | |||||
| Other Income | |||||
| Total Income | |||||
| Purchases and Direct Costs | |||||
| Personnel Expenses | |||||
| Administrative Expenses | |||||
| Interest | |||||
| Depreciation | |||||
| Total Expenses | |||||
| Profit Before Tax | |||||
| Tax | |||||
| Profit After Tax | |||||
| Profit Transferred to Partners | |||||
| Assets and Liabilities | |||||
| Partners' Contribution | |||||
| Reserves and Surplus | |||||
| Secured Loans | |||||
| Unsecured Loans | |||||
| Trade Payables | |||||
| Other Liabilities and Provisions | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Loans and Advances | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | |||||
| Return on Partners' Funds | |||||
| Return on Assets | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Debt to Partners' Funds | |||||
| Interest Coverage | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Turnover Growth | |||||
| Profit Growth | |||||
To see the full financial statements and ratios of Silaris Ingredients LLP, buy the company report.
Designated partners of Silaris Ingredients LLP
Silaris Ingredients has 4 designated partners on record. No former designated partners are listed.
Current Designated Partners
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Alpesh Sangani Ratilal | Designated Partner | 06 Jul 2016 | 10 Years 3 Months | Current |
| Bhavin Ratilal Sangani | Designated Partner | 06 Jul 2016 | 10 Years 3 Months | Current |
| Durgesh Nath Tiwari Also directs: Chromato Scientific Private Limited | Designated Partner | 06 Jul 2016 | 10 Years 3 Months | Current |
| Hemant Baburao Wani | Designated Partner | 06 Jul 2016 | 10 Years 3 Months | Current |
Legal cases
No court or tribunal cases involving Silaris Ingredients LLP are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Silaris Ingredients LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Silaris Ingredients has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27ADCFS4924L1ZQ | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Silaris Ingredients LLP, buy the company report.
Recent activity
Silaris Ingredients LLP has 4 designated partner changes on record since 2016: 4 appointments. The latest: Alpesh Sangani Ratilal was appointed as Designated Partner on 06 Jul 2016.
AGM
Silaris Ingredients Llp last Annual general meeting of members was held on 31 Mar 2025 as per latest MCA records.
Filing
Silaris Ingredients Llp has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Alpesh Sangani Ratilal was appointed as Designated Partner.
Appointed
Bhavin Ratilal Sangani was appointed as Designated Partner.
Appointed
Durgesh Nath Tiwari was appointed as Designated Partner.
Appointed
Hemant Baburao Wani was appointed as Designated Partner.
Incorporation
06 Jul 2016
Silaris Ingredients Llp was registered on 06 Jul 2016 with Roc Mumbai & aged 10 years 3 months as per MCA records.
Frequently asked questions
Silaris Ingredients is an active limited liability partnership based in Mumbai, Maharashtra, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 06 July 2016 (10+ years old) and is registered under LLPIN AAG-8584.
Silaris Ingredients has 4 current designated partners:
- Alpesh Sangani Ratilal - Designated Partner
- Bhavin Ratilal Sangani - Designated Partner
- Durgesh Nath Tiwari - Designated Partner
- Hemant Baburao Wani - Designated Partner
The latest financial statements of Silaris Ingredients on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 March 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Silaris Ingredients is 27ADCFS4924L1ZQ, registered in Maharashtra.
The LLPIN (Limited Liability Partnership Identification Number) of Silaris Ingredients is AAG-8584. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Silaris Ingredients was incorporated on 06 July 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
Alpesh Sangani Ratilal was appointed as Designated Partner on 06 Jul 2016. Bhavin Ratilal Sangani was appointed as Designated Partner on 06 Jul 2016. Durgesh Nath Tiwari was appointed as Designated Partner on 06 Jul 2016. Silaris Ingredients has 4 designated partner changes on record in total.
Yes, Silaris Ingredients is registered as a small enterprise under Udyam registration (number: UDYAM-MH-18-0060879).
The registered office of Silaris Ingredients is at Office No.1002 Shree Radhey Empire Chandavarkar Road Borivali W, Mumbai, Maharashtra, India – 400092.
Silaris Ingredients operates in the pharma industry, in the drug formulation and development segment.